Ligand ID: RO7 Drugbank ID: DB08915(Aleglitazar) Indication:Investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. |
DrReposER ID / Desc. | Hit PDBID |
Hit Macromolecule |
Res. Matches |
View | Interface | RMSD | Seq. Identity (%) |
HETATM | Dock | |
---|---|---|---|---|---|---|---|---|---|---|
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.53A | 17.88 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.55A | 17.88 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 7 | LEU A 286LEU A 242VAL A 204LEU A 272 | 1.51A | 20.72 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 7 | LEU A 250LEU A 272VAL A 204LEU A 242 | 1.79A | 20.72 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 5rfc | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 7 | GLN A 110LEU A 253VAL A 204LEU A 242 | 1.69A | 20.72 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6lxt | SPIKE PROTEIN S2 (SARS-CoV-2) | 5 / 7 | LEU E 984LEU F1166VAL F 976LEU F 981LEU D1166 | 1.51A | 20.88 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.60A | 22.12 | NoneNoneELL D 3 (-3.8A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 4 / 7 | LEU A 242GLN A 110VAL A 204LEU A 250 | 1.44A | 21.94 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.54A | 22.12 | NoneELL D 3 (-3.8A)ELL D 3 (-3.9A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6lze | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 29HIS A 164TYR A 161VAL A 13HIS A 163 | 1.77A | 22.12 | NoneNoneNoneNoneELL D 3 (-3.9A) | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m03 | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.49A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.52A | 22.12 | NoneELL D 3 (-3.7A)ELL D 3 (-3.9A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 29HIS A 164TYR A 161VAL A 13HIS A 163 | 1.76A | 22.12 | NoneNoneNoneNoneELL D 3 (-3.9A) | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m0k | VIRAL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.59A | 22.12 | NoneNoneELL D 3 (-3.7A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY C 29HIS C 164TYR C 161VAL C 13HIS C 163 | 1.76A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 15CYH A 16TYR A 37VAL A 157LEU A 75 | 1.76A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY C 124SER C 144HIS C 163TYR C 161VAL C 13 | 1.52A | 22.74 | None3WL C 401 (-3.7A)NoneNoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY B 120CYH B 117SER B 144TYR B 126VAL B 13 | 1.59A | 22.74 | NoneNone3WL B 401 (-3.6A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 29HIS A 164TYR A 161VAL A 13HIS A 163 | 1.75A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.56A | 22.74 | None3WL A 401 ( 3.8A)NoneNoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY D 29HIS D 164TYR D 161VAL D 13HIS D 163 | 1.77A | 22.74 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | GLN B 110LEU B 253VAL B 204LEU B 242 | 1.36A | 23.71 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY B 124SER B 144HIS B 163TYR B 161VAL B 13 | 1.56A | 22.74 | None3WL B 401 (-3.6A)NoneNoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY C 120CYH C 117SER C 144TYR C 126VAL C 13 | 1.60A | 22.74 | NoneNone3WL C 401 (-3.7A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY D 124SER D 144HIS D 163TYR D 161VAL D 13 | 1.52A | 22.74 | None3WL D 401 ( 3.8A)NoneNoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | GLN A 110LEU A 253VAL A 204LEU A 242 | 1.41A | 23.71 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | LEU B 242GLN B 110VAL B 204LEU B 250 | 1.44A | 23.71 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | GLN D 110LEU D 253VAL D 204LEU D 242 | 1.41A | 23.71 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | LEU A 242GLN A 110VAL A 204LEU A 250 | 1.41A | 23.71 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY D 23LEU D 89VAL D 68LEU D 57TYR D 54 | 1.65A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY B 29HIS B 164TYR B 161VAL B 13HIS B 163 | 1.77A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY D 120CYH D 117SER D 144TYR D 126VAL D 13 | 1.58A | 22.74 | NoneNone3WL D 401 ( 3.8A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.60A | 22.74 | NoneNone3WL A 401 ( 3.8A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m2n | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | LEU D 242GLN D 110VAL D 204LEU D 250 | 1.35A | 23.71 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 4 / 7 | LEU A 242GLN A 110VAL A 204LEU A 250 | 1.39A | 23.71 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.53A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6m2q | 3CL PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.59A | 22.74 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP7 (SARS-CoV-2) | 4 / 7 | GLN C 31LEU C 13VAL C 53LEU C 60 | 1.24A | 18.53 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 146LEU A 241LEU A 131LEU A 251 | 1.39A | 15.47 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP12NSP7 (SARS-CoV-2) | 4 / 7 | LEU A 437LEU C 55VAL C 6LEU C 40 | 1.34A | 15.47 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU C 71GLN C 19LEU C 55LEU D 95 | 1.30A | 18.53 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP7 (SARS-CoV-2) | 4 / 7 | LEU C 20VAL C 58LEU C 14LEU C 71 | 1.39A | 18.53 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU D 95GLN C 19LEU C 28LEU C 55 | 1.31A | 20.07 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP7 (SARS-CoV-2) | 4 / 7 | GLN C 31LEU C 60VAL C 53LEU C 28 | 1.37A | 18.53 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 575LEU A 469VAL A 693LEU A 351 | 1.33A | 15.47 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU C 55VAL C 12LEU D 98LEU C 41 | 1.24A | 18.53 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 316LEU A 207LEU A 186LEU A 142 | 1.30A | 15.47 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 142VAL A 128LEU A 212LEU A 172 | 1.18A | 15.47 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6m71 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 186LEU A 142VAL A 128LEU A 172 | 1.38A | 15.47 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w41 | CR3022 FAB LIGHTCHAINSPIKE PROTEIN S1 (Homosapiens;SARS-CoV-2) | 5 / 12 | GLY C 381SER C 383LEU C 390ILE L 28TYR C 369 | 1.69A | 21.12 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w41 | CR3022 FAB LIGHTCHAINSPIKE PROTEIN S1 (Homosapiens;SARS-CoV-2) | 5 / 12 | GLY C 431SER C 383LEU C 390ILE L 28TYR C 369 | 1.69A | 21.12 | None | ||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w4h | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | VAL A6902CYH B4330CYH B4332ILE B4291VAL B4274 | 1.57A | 21.43 | None ZN B4401 (-2.3A)NoneNoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w4h | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6959VAL A6865LEU A6857LEU A6978 | 1.07A | 21.43 | None | ||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASENSP10 (SARS-CoV-2) | 5 / 12 | VAL A6902CYH B4330CYH B4332ILE B4291VAL B4274 | 1.63A | None ZN B4403 (-2.3A)NoneNoneNone | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6848VAL A6865LEU A7050LEU A7010 | 1.74A | 21.32 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7050LEU A6959VAL A6865LEU A7004 | 1.49A | 21.32 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6981LEU A6857LEU A6959LEU A6848 | 1.58A | 21.32 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6978LEU A6857LEU A6959LEU A6883 | 1.71A | 21.32 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7042LEU A6887VAL A6882LEU A6855 | 1.79A | 21.32 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A7072LEU A6959LEU A7010LEU A6852 | 1.75A | 21.32 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6855GLN A6801LEU A7042LEU A6848 | 1.51A | 21.32 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6959VAL A6865LEU A6857LEU A6978 | 1.06A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6855GLN A6847LEU A7050LEU A7042 | 1.77A | 21.32 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w61 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6848VAL A6865LEU A6857LEU A6981 | 1.51A | 21.32 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.54A | 22.74 | NoneX77 A 401 (-3.4A)X77 A 401 (-4.1A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w63 | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.57A | 22.74 | NoneNoneX77 A 401 (-3.4A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU A 123VAL A 49LEU A 88LEU A 75 | 1.80A | 20.23 | NoneAMP A 201 ( 3.7A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU A 126VAL A 151LYS A 29LEU B 10 | 1.78A | 20.23 | AMP A 201 ( 4.4A)NoneNoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU B 83GLN B 118LEU B 127LEU B 75 | 1.74A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU B 153VAL B 49LEU B 123LEU B 75 | 1.69A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU B 127VAL B 147LEU B 122LEU B 75 | 1.79A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU B 127VAL B 147LEU B 140LEU B 53 | 1.66A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU B 140VAL B 147LEU B 109LEU B 53 | 1.73A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU A 169LEU B 12LEU A 10LEU B 160 | 1.44A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU B 123VAL B 151LEU B 126LEU A 169 | 1.48A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU B 140LEU B 93VAL B 147LEU B 127 | 1.65A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU B 123VAL B 49LEU B 88LEU B 75 | 1.79A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU A 169VAL A 16LEU A 164LEU B 169 | 1.78A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w6y | NSP3 (SARS-CoV-2) | 4 / 7 | LEU A 93LEU A 140VAL A 151LEU A 127 | 1.79A | 20.23 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C7050LEU C6959VAL C6865LEU C7004 | 1.48A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6959VAL A6865LEU A6857LEU A6978 | 1.04A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6981LEU A6857LEU A6959LEU A6848 | 1.58A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6855GLN A6847LEU A7050LEU A7042 | 1.76A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C7072LEU C6959LEU C7010LEU C6852 | 1.76A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C6959VAL C6865LEU C6857LEU C6978 | 1.04A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6855GLN A6801LEU A7042LEU A6848 | 1.49A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A7042LEU A6887VAL A6882LEU A6855 | 1.80A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | VAL C6902CYH D4330CYH D4332ILE D4291VAL D4274 | 1.60A | 22.14 | None ZN D4401 ( 2.3A)NoneNoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6893VAL C7094LEU A6909LEU A6959 | 1.80A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A7050LEU A6959VAL A6865LEU A7004 | 1.48A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C6892VAL C7087LEU C6909LEU C6959 | 1.57A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C6848VAL C6865LEU C7050LEU C7010 | 1.74A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6848VAL A6865LEU A7050LEU A7010 | 1.75A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6848VAL A6865LEU A6857LEU A6981 | 1.54A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A7037VAL A6992LEU A6825LYS A6822 | 1.75A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6978LEU A6857LEU A6959LEU A6883 | 1.68A | 22.14 | None | ||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | VAL A6902CYH B4330CYH B4332ILE B4291VAL B4274 | 1.60A | 22.14 | None ZN B4401 ( 2.3A)NoneNoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w75 | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C6978LEU C6857LEU C6959LEU C6883 | 1.66A | 22.14 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | CYH B 260SER B 278LEU B 101ILE B 123LEU B 282 | 1.78A | 19.82 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 7 | LEU C 178GLN C 122LEU C 172LEU C 101 | 1.35A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 7 | LEU B 178GLN B 122LEU B 172LEU B 101 | 1.40A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | CYH C 260LEU C 118ILE C 123LEU C 282TYR C 296 | 1.79A | 19.82 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 4 / 7 | LEU A 178GLN A 122LEU A 172LEU A 101 | 1.36A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6w9c | PAPAIN-LIKEPROTEINASE (SARS-CoV-2) | 5 / 12 | CYH C 260LEU C 101ILE C 123LEU C 253TYR C 296 | 1.78A | 19.82 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6w9q | 3C-LIKE PROTEINASEPEPTIDE, NSP9 FUSION (SARS-CoV-2) | 4 / 7 | LEU A 42LEU A 4VAL A -6LEU A 97 | 1.42A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU A 55VAL A 12LEU B 98LEU A 41 | 1.30A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wiq | NSP7 (SARS-CoV-2) | 4 / 7 | GLN A 19LEU A 55VAL A 33LEU A 28 | 1.42A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU B 128LEU B 95VAL A 53LEU A 20 | 1.28A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wiq | NSP7NSP8 (SARS-CoV-2) | 5 / 7 | LEU B 128GLN A 31LEU A 13VAL A 53LEU A 60 | 1.76A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6959VAL A6865LEU A6857LEU A6978 | 1.05A | None | |||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wjt | 2'-O-METHYLTRANSFERASENSP10 (SARS-CoV-2) | 5 / 12 | VAL A6902CYH B4330CYH B4332ILE B4291VAL B4274 | 1.64A | None ZN B4401 (-2.3A)NoneNoneNone | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wjt | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU C6959VAL C6865LEU C6857LEU C6978 | 1.12A | None | |||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wjt | 2'-O-METHYLTRANSFERASENSP10 (SARS-CoV-2) | 5 / 12 | VAL C6902CYH D4330CYH D4332ILE D4291VAL D4274 | 1.59A | None ZN D4401 (-2.3A)NoneNoneNone | |||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wkq | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | VAL C6902CYH D4330CYH D4332ILE D4291VAL D4274 | 1.59A | None ZN D4401 ( 2.3A)NoneNoneNone | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU A6959VAL A6865LEU A6857LEU A6978 | 1.06A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C6959VAL C6865LEU C6857LEU C6978 | 1.10A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wkq | NSP16 (SARS-CoV-2) | 4 / 7 | LEU C6848VAL C6865LEU C7050LEU C7073 | 1.26A | None | |||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wkq | NSP10NSP16 (SARS-CoV-2) | 5 / 12 | VAL A6902CYH B4330CYH B4332ILE B4291VAL B4274 | 1.61A | None ZN B4401 ( 2.3A)NoneNoneNone | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 29HIS A 164TYR A 161VAL A 13HIS A 163 | 1.78A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 15CYH A 16LEU A 32VAL A 157LEU A 75 | 1.78A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.54A | 22.74 | NoneU5G A 401 (-4.4A)NoneNoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wnp | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.62A | 22.74 | NoneNoneU5G A 401 (-4.4A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6848VAL A6865LEU A7050LEU A7073 | 1.30A | None | |||
![]() | 3G8I_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wq3 | 2'-O-METHYLTRANSFERASENSP10 (SARS-CoV-2) | 5 / 12 | VAL A6902CYH B4330CYH B4332ILE B4291VAL B4274 | 1.63A | None ZN B4401 (-2.3A)NoneNoneNone | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wq3 | 2'-O-METHYLTRANSFERASE (SARS-CoV-2) | 4 / 7 | LEU A6959VAL A6865LEU A6857LEU A6978 | 1.04A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU D 128LEU D 95VAL C 53LEU C 20 | 1.24A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU A 71LEU B 128VAL B 115LEU A 35 | 1.33A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU B 128LEU B 95VAL A 53LEU A 20 | 1.23A | NoneNoneEDO B 302 ( 4.8A)None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7 (SARS-CoV-2) | 4 / 7 | LEU C 59VAL C 22LEU C 55LEU A 14 | 1.39A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7 (SARS-CoV-2) | 4 / 7 | LEU A 59VAL A 22LEU A 55LEU C 14 | 1.44A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU A 55VAL A 12LEU B 98LEU A 41 | 1.27A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU D 91GLN A 18LEU A 55LEU A 40 | 1.37A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU B 91GLN C 18LEU C 55LEU C 40 | 1.44A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 7 | LEU C 40LEU D 95VAL C 6LEU C 55LEU A 40 | 1.79A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 7 | LEU B 128GLN A 31LEU A 13VAL A 53LEU A 60 | 1.72A | NoneNoneNoneEDO B 302 ( 4.8A)None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU C 55VAL C 12LEU D 98LEU C 41 | 1.28A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU B 95VAL A 16LEU A 55LEU D 91 | 1.33A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU C 14GLN B 88LEU A 55VAL A 11 | 1.31A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU D 95VAL C 16LEU C 55LEU B 91 | 1.37A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU A 14GLN D 88LEU C 55VAL C 11 | 1.31A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 7 | LEU D 128GLN C 31LEU C 13VAL C 53LEU C 60 | 1.79A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 7 | GLN A 31LEU A 60VAL A 53LEU B 128LEU A 28 | 1.77A | NoneNoneEDO B 302 ( 4.8A)NoneNone | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 5 / 7 | LEU A 40LEU B 95VAL A 6LEU A 55LEU C 40 | 1.61A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqd | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU C 71LEU D 128VAL D 115LEU C 35 | 1.30A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.60A | 22.74 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 4 / 7 | LEU A 242GLN A 110VAL A 204LEU A 250 | 1.35A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6wqf | 3C-LIKE PROTEINASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.53A | 22.74 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 7 | LEU A 250LEU A 272VAL A 204LEU A 242 | 1.78A | 20.72 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | GLY A 29HIS A 164TYR A 161VAL A 13HIS A 163 | 1.79A | 17.88 | NoneNoneNoneNoneDMS A 405 (-3.9A) | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 7 | LEU A 286LEU A 242VAL A 204LEU A 272 | 1.53A | 20.72 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.64A | 17.88 | NoneNoneDMS A 405 ( 3.7A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.53A | 17.88 | NoneDMS A 405 ( 3.7A)DMS A 405 (-3.9A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yb7 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 7 | GLN A 110LEU A 253VAL A 204LEU A 242 | 1.71A | 20.72 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU A 55VAL A 12LEU B 98LEU A 41 | 1.26A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 7 | LEU C 40LEU D 95VAL C 6LEU C 55LEU A 40 | 1.69A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU B 128LEU B 95VAL A 53LEU A 20 | 1.33A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU A 40GLN A 19LEU C 55VAL C 16 | 1.30A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU C 55VAL C 12LEU D 98LEU C 41 | 1.24A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU C 71LEU D 128VAL D 115LEU C 35 | 1.30A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU B 91GLN C 18LEU C 55LEU C 40 | 1.38A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU C 14GLN B 88LEU A 55VAL A 11 | 1.30A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 5 / 7 | LEU A 40LEU B 95VAL A 6LEU A 55LEU C 40 | 1.72A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU D 91GLN A 18LEU A 55LEU A 40 | 1.35A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU D 95VAL C 16LEU C 55LEU B 91 | 1.33A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU A 14GLN D 88LEU C 55VAL C 11 | 1.26A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU B 95VAL A 16LEU A 55LEU D 91 | 1.35A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU A 17GLN A 63LEU A 71LEU A 56 | 1.38A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU D 128LEU D 95VAL C 53LEU C 20 | 1.29A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6yhu | REPLICASEPOLYPROTEIN 1A (SARS-CoV-2) | 4 / 7 | LEU A 71LEU B 128VAL B 115LEU A 35 | 1.27A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.53A | 22.74 | NoneNoneP6N A 502 (-3.3A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.53A | 22.74 | NoneP6N A 502 (-3.3A)P6N A 502 (-3.8A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 6ynq | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 4 / 7 | LEU A 242GLN A 110VAL A 204LEU A 250 | 1.41A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.52A | 22.74 | NoneDMS A 403 ( 2.9A)DMS A 403 (-4.1A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 6yt8 | REPLICASEPOLYPROTEIN 1AB (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.54A | 22.74 | NoneNoneDMS A 403 ( 2.9A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.53A | 22.74 | NonePJE C 5 ( 4.1A)PJE C 5 (-3.8A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 15CYH A 16TYR A 37VAL A 157LEU A 75 | 1.79A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 23LEU A 89VAL A 68LEU A 57TYR A 54 | 1.65A | 22.74 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 29HIS A 164TYR A 161VAL A 13HIS A 163 | 1.79A | 22.74 | NoneNoneNoneNonePJE C 5 (-3.8A) | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bqy | MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.60A | 22.74 | NoneNonePJE C 5 ( 4.1A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU C 55VAL C 12LEU D 98LEU C 41 | 1.23A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU D 128LEU D 95VAL C 53LEU C 20 | 1.35A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP12NSP7 (SARS-CoV-2) | 4 / 7 | GLN A 444LEU C 55VAL C 11LYS C 51 | 1.42A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP7 (SARS-CoV-2) | 4 / 7 | GLN C 31LEU C 60VAL C 53LEU C 28 | 1.37A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 316LEU A 207LEU A 186LEU A 142 | 1.26A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7btf | NSP12NSP8 (SARS-CoV-2) | 5 / 12 | SER A 397TYR B 149LEU B 128VAL B 186ILE B 185 | 1.77A | 15.77 | None | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7btf | NSP12 (SARS-CoV-2) | 5 / 12 | GLY A 214HIS A 99TYR A 87LEU A 90LEU A 119 | 1.67A | 15.77 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 146LEU A 241LEU A 131LEU A 251 | 1.34A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 186LEU A 142VAL A 128LEU A 172 | 1.37A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP12NSP7 (SARS-CoV-2) | 4 / 7 | LEU C 55GLN A 444VAL C 22LEU A 544 | 1.43A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 186VAL A 234LEU A 207LEU A 470 | 1.43A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 142VAL A 128LEU A 212LEU A 172 | 1.21A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7btf | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU D 95GLN C 19LEU C 28LEU C 55 | 1.42A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 29HIS A 164TYR A 161VAL A 13HIS A 163 | 1.77A | 22.74 | NoneNoneNoneNoneDMS A 402 (-3.9A) | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 120CYH A 117SER A 144TYR A 126VAL A 13 | 1.59A | 22.74 | NoneNoneDMS A 402 ( 3.6A)NoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 4 / 7 | LEU A 242GLN A 110VAL A 204LEU A 250 | 1.42A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 124SER A 144HIS A 163TYR A 161VAL A 13 | 1.50A | 22.74 | NoneDMS A 402 ( 3.6A)DMS A 402 (-3.9A)NoneNone | ||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7buy | VIRUS MAIN PROTEASE (SARS-CoV-2) | 5 / 12 | GLY A 15CYH A 16LEU A 32VAL A 157LEU A 75 | 1.79A | 22.74 | DMS A 403 (-3.7A)NoneNoneNoneNone | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 186LEU A 142VAL A 128LEU A 172 | 1.42A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 146LEU A 241LEU A 131LEU A 251 | 1.30A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv1 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 142VAL A 128LEU A 212LEU A 172 | 1.23A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bv1 | NSP8 (SARS-CoV-2) | 5 / 12 | GLY D 144CYH D 142TYR D 135VAL D 186ILE D 156 | 1.67A | 19.57 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv1 | NSP7NSP8 (SARS-CoV-2) | 4 / 7 | LEU C 55VAL C 12LEU D 98LEU C 41 | 1.27A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv1 | NSP12NSP8 (SARS-CoV-2) | 4 / 7 | LEU B 117VAL A 342LEU B 103LEU A 401 | 1.28A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv1 | NSP7 (SARS-CoV-2) | 4 / 7 | GLN C 19LEU C 55VAL C 33LEU C 28 | 1.40A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 146LEU A 241LEU A 131LEU A 251 | 1.32A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 186VAL A 234LEU A 207LEU A 470 | 1.36A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 207LEU A 146LEU A 212LEU A 172 | 1.42A | None | |||
![]() | 3G9E_A_RO7A1_1 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR GAMMA) | 7bv2 | NSP12 (SARS-CoV-2) | 5 / 12 | GLY A 337SER A 363LEU A 361LEU A 366TYR A 374 | 1.55A | 15.25 | None | ||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 361GLN A 357VAL A 342LYS A 369 | 1.37A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 142VAL A 128LEU A 212LEU A 172 | 1.21A | None | |||
![]() | 3G8I_A_RO7A1_2 (PEROXISOMEPROLIFERATOR-ACTIVATED RECEPTOR ALPHA) | 7bv2 | NSP12 (SARS-CoV-2) | 4 / 7 | LEU A 316LEU A 207LEU A 186LEU A 142 | 1.28A | None |